Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LIQ001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fluzone + 0.45 mg LIQ001 | EXPERIMENTAL | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg) |
| Fluzone + 1.8 mg LIQ001 | EXPERIMENTAL | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg) |
| Fluzone | ACTIVE_COMPARATOR | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) |
| Name | Type | Description |
|---|---|---|
| Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) | BIOLOGICAL | A single vaccination of Fluzone alone |
| LIQ001 (0.45mg) | BIOLOGICAL | A single vaccination of 0.45 mg LIQ001 |
| LIQ001 (1.8mg) | BIOLOGICAL | A single vaccination of 1.8 mg LIQ001 |
Inclusion Criteria: * Age 18 to 49 years (Cohort 1) and age 65 or above (Cohort 2) * For subjects 18 to 49 years of age: in good health as determined by medical history, physical examination, and the clinical judgment of the Principal Investigator (PI) * For subjects 65 years of age and older: in s...
LIQ001 is an investigational monoclonal antibody being studied for use in influenza. It is currently in Phase 1 clinical development and is not yet approved by the FDA. The drug is being evaluated for its safety and tolerability in a clinical trial setting.
LIQ001 is being developed by Liquidia Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol LQDA. The company is conducting clinical research to evaluate the drug's potential as a treatment for influenza.
LIQ001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for influenza.
LIQ001 has been studied in a Phase 1 clinical trial registered as NCT01224262. This completed trial evaluated the safety and tolerability of a seasonal influenza vaccine containing LIQ001 in 152 healthy adult volunteers in the United States.
LIQ001 is a monoclonal antibody that was evaluated in a clinical trial as part of a seasonal influenza vaccine. The trial, NCT01224262, assessed the safety and tolerability of the vaccine containing LIQ001, but LIQ001 itself is the investigational drug being studied.